株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心臓バイオマーカーの世界市場:考察、機会、分析、市場シェア、および予測

Global Cardiac Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 361000
出版日 ページ情報 英文 140 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
心臓バイオマーカーの世界市場:考察、機会、分析、市場シェア、および予測 Global Cardiac Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022
出版日: 2016年06月08日 ページ情報: 英文 140 Pages
概要

世界の心臓バイオマーカー市場規模は、2016年から2022年にかけて19.5%のCAGR (年間複合成長率) で推移し、2022年までに22億2,590万米ドルに達すると予測されています。

当レポートでは、世界の心臓バイオマーカー市場について分析し、今後の市場規模・成長率の見通し、検査場所・タイプ・アプリケーション別の詳細動向、主要企業のプロファイルと市場シェア、各地域・主要国市場の構造・動向見通しなどについて調査・推計しております。

第1章 イントロダクション

第2章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • パラメーター分析
  • 主な市場考察
    • 新興諸国トップ3
    • 収益生成区分トップ3
    • 成長市場・新興動向トップ3
    • 地域トップ3
  • 競争環境
    • 市場シェア分析
    • 主な成功戦略
    • ケーススタディ:市場競争の主な動き
  • ポーターのファイブフォースモデル
  • 主な購入基準
  • 戦略的提言
  • 結論

第3章 市場決定要因

  • 市場促進要因
    • 心血管疾患の罹患率の増加
    • コスト効果的な装置
    • 非侵襲手法
    • 予測の精度
    • 治験に役立つ
    • マルチアプリケーション
    • 心臓バイオマーカーのコンビネーションを用いた技術進歩
    • ポイントオブケア (POC) アプリケーションの増加
  • 市場抑制要因
    • 政府規制
    • 結果での確認
    • 複雑な製造工程
  • 市場機会
    • オーダーメイド医療の需要
    • 心臓バイオマーカーを用いたポイントオブケア (POC) 検査
    • 新規の心臓バイオマーカーにおける将来の発展
  • 市場の課題
    • 臨床的妥当性の認可・バイオマーカー型試験の活用
  • 母体市場
  • 競合市場
  • 代替的市場

第4章 市場区分

  • 検査場所別
    • ポイントオブケア(POC)
    • ラボ検査
  • タイプ別
    • クレアチンキナーゼ (CK-MB)
    • トロポニン (T, I)
    • ミオグロビン
    • ナトリウム利尿ペプチド (BNP・NT-PROBNP)
    • 虚血変更アルブミン
    • その他
  • アプリケーション別
    • 心筋梗塞
    • うっ血性心不全
    • 急性冠症候群 (ACS)
    • アテローム性動脈硬化
    • その他

第5章 地域分析

  • 北米の心臓バイオマーカー市場
    • 米国
    • カナダ
  • 欧州の心臓バイオマーカー市場
    • 英国
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • その他
  • アジア太平洋の心臓バイオマーカー市場
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • その他
  • 他の国々 (RoW) の心臓バイオマーカー市場
    • ラテンアメリカ
    • 中東・北アフリカ (MENA)
    • アフリカ

第6章 企業プロファイル

  • ABBOTT DIAGNOSTICS
  • ALERE INC.
  • BECKMAN COULTER
  • BECTON, DICKINSON AND CO.
  • BG MEDICINE INC.
  • BIOMERIEUX
  • EKF DIAGNOSTICS HOLDINGS, INC.
  • MERCK & CO, INC.
  • RADIOMETER MEDICAL
  • RANDOX LABORATORY
  • RESPONSE BIOMEDICAL
  • ROCHE HOLDING AG
  • SIEMENS HEALTHCARE
  • SINGULEX
  • THERMO FISHER SCIENTIFIC

図表一覧

目次
Product Code: HME-1521015

The global cardiac biomarker market is expected to generate the revenue of $2,225.9 million by 2022, registering a CAGR of 19.5% from 2016 to 2022. The prevention of cardiac diseases, by active monitoring the heart conditions by using cardiac biomarker testing is the newest approach for obtaining fastest output of immediate diagnosing and treatment of cardiac deceases. Cardiac biomarkers are made by protein-based traceable substances used as an indicator to assess biological state and for diagnosing the proactive purposes associated with heart. Cardiac biomarkers are also used as risk calculation for various cardiovascular diseases (CVDs), including myocardial congestive heart failure, infraction, acute coronary syndrome (ACS) among others deceases.

The promising features of markers such as high accuracy, rapid outcomes and affordable pricing of cardiac point of care (POC) testing is supporting the market of cardiac biomarker for the growth, worldwide. To keep the momentum stable of cardiac marker tests, the key manufacturers offers customized solutions. However, limited availability in some cases and side effects such as skeletal muscle injury is hindering the growth of cardiac biomarkers market. However, concerns related to single measurement cardiac biomarkers, high pricing of the devices and certain government regulations is expected to restrain the market to grow.

The global cardiac biomarkers market is basically segmented on the basis of type, application, location of testing and geography. Based on type of cardiac biomarkers, the market is divided into Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA and others. Troponins I and T are the largest revenue-generating segment in the overall cardiac biomarkers market because of its prodigious specialty and its ability to detect accurately the cardiac events of Acute Coronary Syndrome (ACS).

Based on application segment, the market is subdivided into myocardial infarction, congestive heart failure, atherosclerosis acute coronary syndrome, and others. Myocardial infarction (MI) accounts the highest market share in the global cardiac biomarker market and it is followed by acute coronary syndrome (ACS) because of its highest prevalence rate in all the cardiovascular diseases (CVDs). The location of testing segment is classified under point of care testing and laboratory testing. Doctors and clinicians majorly use point of care cardiac testing for quick monitoring and diagnosing patients with having chest pain in an emergency care unit, therefore, it accounts for the fastest growing CAGR in the forecasted period. However, laboratory testing segment is generating larger revenue in comparison to point of care testing now-a-days.

On the basis of geography, the global cardiac biomarker market is divided into North America, Europe, Asia-Pacific and LAMEA. Out of which North America is leading the global market, owing to the high demand for cardiac testing, high CVD prevalence rates and growing awareness towards cardiac diagnostics solutions. Asia-Pacific is emerging region with fastest growing CAGR due to the modernization in the countries, increasing disposable incomes and increasing affordability for the advanced cardiac treatments.

Key companies working in this market are Roche Diagnostics, Siemens Healthcare, Becton, Alere Inc., BioMerieux, Abbott Laboratories, Bio-Rad Laboratories, Dickinson and Company, Randox laboratories, Beckman Coulter and Thermo Fisher Scientific. Product launch and technological advancements are the few strategies adopted by the key players of global market. Biomarkers production companies are currently focusing on innovative technologies such as automated, multi-assay using combinations of cardiac biomarkers and point-of-care cardiac biomarker devices.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. MARKET DEFINITION AND SCOPE
  • 2.2. KEY FINDINGS
  • 2.3. PARAMETRIC ANALYSIS
  • 2.4. KEY MARKET INSIGHTS
    • 2.4.1. TOP 3 EMERGING COUNTRIES
    • 2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
    • 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
    • 2.4.4. TOP 3 GEOGRAPHY
  • 2.5. COMPETITIVE LANDSCAPE
    • 2.5.1. MARKET SHARE ANALYSIS
    • 2.5.2. TOP WINNING STRATEGIES
    • 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
  • 2.6. PORTER'S FIVE FORCE MODEL
    • 2.6.1. THREAT OF NEW ENTRANTS
    • 2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 2.6.3. BARGAINING POWER OF BUYER
    • 2.6.4. BARGAINING POWER OF SUPPLIER
    • 2.6.5. INTENSITY OF COMPETITIVE RIVALRY
  • 2.7. KEY BUYING CRITERIA
  • 2.8. STRATEGIC RECOMMENDATION
  • 2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. RISING PREVALENCE OF CARDIOVASCULAR DISEASES
    • 3.1.2. COST EFFECTIVE DEVICE
    • 3.1.3. NON-INVASIVE METHOD
    • 3.1.4. ACCURACY IN PREDICTION
    • 3.1.5. HELPFUL IN CLINICAL TRIALS
    • 3.1.6. MULTI-APPLICATION
    • 3.1.7. TECHNOLOGICAL ADVANCEMENTS USING CARDIAC BIOMARKERS COMBINATIONS
    • 3.1.8. INCREASING POINT OF CARE (POC) APPLICATION
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. GOVERNMENT REGULATIONS
    • 3.2.2. CONFIRMATION IN RESULT
    • 3.2.3. COMPLEX PRODUCTION PROCESS
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. DEMAND OF PERSONALIZED MEDICINE
    • 3.3.2. POINT OF CARE (POC) TESTING USING CARDIAC BIOMARKERS
    • 3.3.3. FUTURE DEVELOPMENTS IN NOVEL CARDIAC BIOMARKERS
  • 3.4. MARKET CHALLENGES
    • 3.4.1. APPROVAL CLINICAL VALIDITY AND UTILITY OF BIOMARKERS-BASED TESTS
  • 3.5. PARENT MARKET
  • 3.6. COMPETITORS MARKET
  • 3.7. ALTERNATIVE MARKET

4. MARKET SEGMENTATION

  • 4.1. BY LOCATION OF TESTING
    • 4.1.1. POINT OF CARE
    • 4.1.2. LABORATORY TESTING
  • 4.2. BY TYPE
    • 4.2.1. CREATINE KINASE (CK-MB)
    • 4.2.2. TROPONINS(T,I)
    • 4.2.3. MYOGLOBIN
    • 4.2.4. NATRIURETIC PEPTIDES (BNP AND NT-PROBNP)
    • 4.2.5. ISCHEMIA MODIFIED ALBUMIN
    • 4.2.6. OTHERS
  • 4.3. BY APPLICATION
    • 4.3.1. MYOCARDIAL INFARCTION
    • 4.3.2. CONGESTIVE HEART FAILURE
    • 4.3.3. ACUTE CORONARY SYNDROME
    • 4.3.4. ATHEROSCLEROSIS
    • 4.3.5. OTHERS

5. GEOGRAPHICAL ANALYSIS

  • 5.1. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.1.1. UNITED STATES (U.S.) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.1.2. CANADA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 5.2. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.1. UNITED KINGDOM (UK) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.2. FRANCE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.3. GERMANY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.4. SPAIN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.5. ITALY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.6. ROE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 5.3. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.1. INDIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.2. CHINA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.3. JAPAN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.4. KOREA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.5. AUSTRALIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.6. ROAPAC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 5.4. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.4.1. LATIN AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.4.2. MENA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.4.3. AFRICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)

6. COMPANY PROFILE

  • 1. ABBOTT DIAGNOSTICS
  • 2. ALERE INC.
  • 3. BECKMAN COULTER
  • 4. BECTON, DICKINSON AND CO.
  • 5. BG MEDICINE INC.
  • 6. BIOMERIEUX
  • 7. EKF DIAGNOSTICS HOLDINGS, INC.
  • 8. MERCK & CO, INC.
  • 9. RADIOMETER MEDICAL
  • 10. RANDOX LABORATORY
  • 11. RESPONSE BIOMEDICAL
  • 12. ROCHE HOLDING AG
  • 13. SIEMENS HEALTHCARE
  • 14. SINGULEX
  • 15. THERMO FISHER SCIENTIFIC

LIST OF TABLES

  • 1. GLOBAL CARDIAC BIOMARKERS MARKET BY LOCATION OF TESTING 2014-2022 ($ MILLION)
  • 2. GLOBAL CARDIAC BIOMARKERS MARKET BY POINT OF CARE 2014-2022 ($ MILLION)
  • 3. GLOBAL CARDIAC BIOMARKERS MARKET BY LABORATORY TESTING 2014-2022 ($ MILLION)
  • 4. GLOBAL CARDIAC BIOMARKERS MARKET BY TYPE 2014-2022 ($ MILLION)
  • 5. GLOBAL CARDIAC BIOMARKERS MARKET BY CREATINE KINASE (CK-MB) 2014-2022 ($ MILLION)
  • 6. GLOBAL CARDIAC BIOMARKERS MARKET BY TROPONINS(T,I) 2014-2022 ($ MILLION)
  • 7. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOGLOBIN 2014-2022 ($ MILLION)
  • 8. GLOBAL CARDIAC BIOMARKERS MARKET BY NATRIURETIC PEPTIDES (BNP AND NT-PROBNP) 2014-2022 ($ MILLION)
  • 9. GLOBAL CARDIAC BIOMARKERS MARKET BY ISCHEMIA MODIFIED ALBUMIN 2014-2022 ($ MILLION)
  • 10. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
  • 11. GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION 2014-2022 ($ MILLION)
  • 12. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOCARDIAL INFARCTION 2014-2022 ($ MILLION)
  • 13. GLOBAL CARDIAC BIOMARKERS MARKET BY CONGESTIVE HEART FAILURE 2014-2022 ($ MILLION)
  • 14. GLOBAL CARDIAC BIOMARKERS MARKET BY ACUTE CORONARY SYNDROME 2014-2022 ($ MILLION)
  • 15. GLOBAL CARDIAC BIOMARKERS MARKET BY ATHEROSCLEROSIS 2014-2022 ($ MILLION)
  • 16. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
  • 17. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 18. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 19. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 20. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CARDIAC BIOMARKERS MARKET BY POINT OF CARE 2014-2022 ($ MILLION)
  • 2. GLOBAL CARDIAC BIOMARKERS MARKET BY LABORATORY TESTING 2014-2022 ($ MILLION)
  • 3. GLOBAL CARDIAC BIOMARKERS MARKET BY CREATINE KINASE (CK-MB) 2014-2022 ($ MILLION)
  • 4. GLOBAL CARDIAC BIOMARKERS MARKET BY TROPONINS(T,I) 2014-2022 ($ MILLION)
  • 5. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOGLOBIN 2014-2022 ($ MILLION)
  • 6. GLOBAL CARDIAC BIOMARKERS MARKET BY NATRIURETIC PEPTIDES (BNP AND NT-PROBNP) 2014-2022 ($ MILLION)
  • 7. GLOBAL CARDIAC BIOMARKERS MARKET BY ISCHEMIA MODIFIED ALBUMIN 2014-2022 ($ MILLION)
  • 8. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
  • 9. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOCARDIAL INFARCTION 2014-2022 ($ MILLION)
  • 10. GLOBAL CARDIAC BIOMARKERS MARKET BY CONGESTIVE HEART FAILURE 2014-2022 ($ MILLION)
  • 11. GLOBAL CARDIAC BIOMARKERS MARKET BY ACUTE CORONARY SYNDROME 2014-2022 ($ MILLION)
  • 12. GLOBAL CARDIAC BIOMARKERS MARKET BY ATHEROSCLEROSIS 2014-2022, ($ MILLION)
  • 13. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
  • 14. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 15. UNITED STATES (U.S.) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 16. CANADA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 17. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 18. UNITED KINGDOM (UK) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 19. FRANCE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 20. GERMANY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 21. SPAIN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 22. ITALY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 23. ROE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 24. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 25. INDIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 26. CHINA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 27. JAPAN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 28. KOREA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 29. AUSTRALIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 30. ROAPAC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 31. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 32. LATIN AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 33. MENA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 34. AFRICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
Back to Top